17,261 trials
Type 1 Diabetes Mellitus · Dyslipidemia
Primary: Change in LDL-c From Baseline to 6 Months in Subjects With Type 1 Diabetes Taking Vytorin or Zocor. — -67; -6 mg/dl
Hypertension
Primary: Pharmacokinetics of Subcutaneous (SC) PL-3994 Relative to Placebo in Subjects With Controlled Hypertension. — 0; 0.366; 0 ng/mL
End Stage Renal Failure on Dialysis · Complication of Hemodialysis
Primary: Interleukin 1 Beta — 6.18; 2.16; 1.44 pg/mL
Rheumatoid Arthritis
Primary: Percentage of American College of Rheumatology [ACR] 50 Criteria Responders at Week 12 — 9.9; 23.4; 26.5; 11.4 percentage of participants
Breakthrough Bleeding
Primary: Days With Bleeding and/or Spotting During Active Cycle 1 (Day 1-84) — 13; 13.5; 15; 15 days
Bipolar I Disorder
Primary: Proportion of Patients Who Showed no Worsening According to the Clinical Global Impression - Bipolar Version (CGI-BP) Scale (Intent-to-Treat Population) — 26; 14; 16…
Prostatic Neoplasms · Prostate Cancer
Primary: Percentage of Participants With Prostate Specific Antigen (PSA) Response — 37.9 percentage of participants
Adult Anaplastic Astrocytoma · Adult Anaplastic Ependymoma · Adult Anaplastic Meningioma
Primary: Number of Participants With Response ( > 25% Reduction in T2 Flair) From Baseline to Evaluation at 6 Weeks Post Treatment — 5; 6 participants
Autism Spectrum Disorders
Primary: Irritability Subscale of the Aberrant Behavior Checklist, Community Version — -8.9 Points on a scale
Lymphoma · Leukemia
Primary: Number of Participants With Graft Failure — 1 participants
Macular Degeneration
Primary: Number of Participants With Adverse Events (AE) — 154; 138; 151; 5 participants
Hemophilia A
Primary: Proportion of Subjects With Major Response, i.e. Inhibitor Level Falls to Less Than 5 BU/mL Between Weeks 6 to 22 and Remains Below 5 BU/mL at 5-7 Days Following…
Sleep Apnea · Stroke
Primary: Apnea-hypopnea Index — 27; 39 events/hr — p=0.011
Colorectal Cancer
Primary: The Percentage of Patients Experiencing Treatment-related Gastrointestinal Adverse Events ≥ Grade 2 Per National Cancer Institute (NCI) Common Terminology Criteria for…
Kidney Cancer
Primary: Clinical Response as Measured by RECIST — 50 percentage of participants